Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

This study has been withdrawn prior to enrollment.
(Sponsor withdrew due to funding issues)
Sponsor:
Collaborator:
CTI BioPharma
Information provided by:
University of Southern California
ClinicalTrials.gov Identifier:
NCT01227408
First received: January 8, 2009
Last updated: May 19, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)